155 Results for "

GLP1R

" in MedChemExpress (MCE) Product Catalog:
Products (155)

155 Results for "GLP1R" in MCE Product Catalog:

45
45 Publications Verification
Cat. No.: HY-114118
CAS No.: 910463-68-2
Purity:  99.84%
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer [1] .
loading...
    loading...
45
45 Publications Verification
Cat. No.: HY-114118B
CAS No.: 1997361-85-9
Purity:  99.92%
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer [1] .
loading...
    loading...
45
45 Publications Verification
Cat. No.: HY-P0264A
CAS No.: 2051593-46-3
Synonyms: Avexitide acetate
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

Exendin(9-39) amide (Avexitide) acetate is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for the GLP-1R, counteracting the effects of excessive GLP-1 secretion. Exendin(9-39) amide acetate can be utilized in Postbariatric hypoglycemia (PBH) research [1].
loading...
    loading...
45
45 Publications Verification
Cat. No.: HY-114118A
Purity:  99.92%
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer [1] .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-101116
CAS No.: 488097-06-9
Purity:  99.67%
Target:  

GCGR

Research Areas:  

Metabolic Disease

GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM [1].
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-125824
CAS No.: 2230198-02-2
Purity:  99.85%
Synonyms: PF-06882961
Target:  

GCGR

Research Areas:  

Metabolic Disease

Danuglipron (PF-06882961) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron has the potential for type 2 diabetes research [1] .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P3506
CAS No.: 2381089-83-2
Synonyms: LY3437943
Target:  

GCGR GLP Receptor

Research Areas:  

Metabolic Disease

Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity [1].
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P3506A
Synonyms: LY3437943 TFA
Target:  

GLP Receptor GCGR

Research Areas:  

Metabolic Disease

Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity [1].
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P3506B
Synonyms: LY3437943 acetate
Target:  

GCGR GLP Receptor

Research Areas:  

Metabolic Disease

Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity [1].
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-112185
CAS No.: 2212020-52-3
Purity:  99.80%
Synonyms: LY3502970; GLP-1 receptor agonist 1
Target:  

GCGR

Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete [1].
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-112185A
CAS No.: 3008544-96-2
Purity:  99.71%
Synonyms: LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate
Target:  

GCGR

Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) is the calcium salt hydrate form of Orforglipron (HY-112185). Orforglipron is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorating the type 2 diabete [1].
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P81160
Synonyms: Glucagon like peptide-1 receptor; GLP 1 R; GLP 1 receptor; GLP 1R; GLP1R; GLP; GLP1R; Glucagon like peptide 1 receptor; RATGL1RCP; Glip; MGC138331; GLP-1-R; GLP1R_HUMAN; Glucagon-like peptide 1 receptor; GLP-1 receptor; GLP-1-R; GLP-1R; Precursor.

Host:  

Rabbit

Application:  

WB, IHC-P, IHC-F, ICC/IF, FC

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P700468
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rHuGlucagon-like peptide 1 receptor/GLP1R, Fc; Glucagon-like peptide 1 receptor; GLP-1 receptor; GLP-1-R
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P72206
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: GLP1R; Glucagon-like peptide 1 receptor; GLP-1 receptor; GLP-1-R; GLP-1R
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P3291
CAS No.: 2296814-85-0
Synonyms: ZP7570
Target:  

GCGR

Research Areas:  

Metabolic Disease

Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects [1] .
loading...
    loading...
Cat. No.: HY-P3375
CAS No.: 2259884-03-0
Synonyms: IBI-362; LY-3305677; OXM-3
Target:  

GCGR GLP Receptor

Research Areas:  

Metabolic Disease

Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) [1] .
loading...
    loading...
Cat. No.: HY-121835
CAS No.: 281209-71-0
Purity:  99.94%
Target:  

GCGR

Research Areas:  

Metabolic Disease

GLP-1R agonist 2 (compound 2) is an effective GLP-1R agonist that exerts its activating effect by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues of GLP-1R. GLP-1R agonist 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity [1].
loading...
    loading...
Cat. No.: HY-160734
CAS No.: 2685823-26-9
Synonyms: GSBR-1290
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

Aleniglipron (GSBR-1290) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist, with an EC50 value of less than 0.1 nM in HDB cell lines in cAMP stimulation assays. Aleniglipron selectively activates the Gαs-cAMP signaling pathway of GLP-1R without β-arrestin recruitment. Aleniglipron induces insulin release, promotes glucose clearance, reduces food intake and decreases body weight. Aleniglipron is applicable to research related to type 2 diabetes and obesity [1] .
loading...
    loading...
Cat. No.: HY-153865
CAS No.: 2401892-75-7
Purity:  99.68%
Synonyms: PF-07081532
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

Lotiglipron (PF-07081532) is an orally active GLP-1R agonist. Lotiglipron reduces glucose and body weight, and can be used for research of Type 2 diabetes mellitus (T2DM) [1].
loading...
    loading...
Cat. No.: HY-177295
CAS No.: 2572566-11-9
Synonyms: LY3549492
Naperiglipron (LY3549492) is an orally active Glucagon-like peptide 1 receptor (GLP-1R) agonist with an EC50 of 1.14 nM for hGLP-1R. Naperiglipron significantly decreases the level of blood glucose in GLP-1R knock-in mouse models. Naperiglipron inhibits PDE10A1 enzyme activity (IC50: 7.43 μM) with a weak hERG inhibitory activity. Naperiglipron can be used for type II diabetes mellitus (T2DM) and obesity research [1].
loading...
    loading...